Elite Pharmaceuticals, Inc.
ELTP
$0.40
-$0.021-4.99%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -10.89M | -11.04M | 615.80K | 3.33M | 706.40K |
| Total Depreciation and Amortization | 489.60K | 553.50K | 558.70K | 461.30K | 350.50K |
| Total Amortization of Deferred Charges | 3.50K | 3.50K | 3.50K | -- | -- |
| Total Other Non-Cash Items | 11.91M | 14.20M | 2.91M | -22.07M | 3.49M |
| Change in Net Operating Assets | -2.58M | -2.26M | -942.50K | 20.34M | -6.93M |
| Cash from Operations | -1.06M | 1.46M | 3.14M | 2.06M | -2.39M |
| Capital Expenditure | 0.00 | -92.40K | -778.50K | -403.60K | -406.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 110.00K | 15.30K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 0.00 | -900.00K | -- | -- |
| Cash from Investing | 0.00 | 17.60K | -1.66M | -403.60K | -406.00K |
| Total Debt Issued | -- | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -193.10K | -320.70K | -174.90K | -401.00K | -37.60K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 39.50K | -- |
| Cash from Financing | -193.10K | -320.70K | -174.90K | -361.40K | -37.60K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.26M | 1.15M | 1.31M | 1.29M | -2.83M |